

## Bederra Corporation Closes Long Term Financing

Wednesday April 9, 8:45 am ET

HOUSTON, TX--(MARKET WIRE)--Apr 9, 2008 -- Bederra Corporation (Other OTC:[BDRR.PK](#) - [News](#)), a medical imaging and diagnostic Company, is pleased to announce it has closed on its current financing needs.

The company was able to secure both traditional bank financing and debt financing through the issuance of a promissory note that bears interest quarterly. This financing allows the company to cover all of its current capital requirements. The funds were raised to bridge the accounts receivable from its recent acquisitions.

In order to build shareholder value, the company will not pursue any additional equity financing for expansion until it has achieved a sufficient market cap to support additional growth. This is to insure that any future additional equity issuance would be accretive to current shareholders.

Graham Williams, Bederra Corporation CEO, stated, "Our recent financing activities have satisfied our current capital needs. As new developments are announced and our financials are released, we expect the investment community to recognize that we are severely undervalued by the current market. Our accountants are finalizing our financials. As soon as they are completed we will release them to our shareholders."

### About Bederra Corporation

Bederra Corporation, which wholly owns Diagnos, Inc. and Lumar Imaging, Inc., provides multiple modality diagnostic medical imaging services to the greater Houston area and world famous Texas medical center. The company's current strategy is to grow its current operations and seek out additional acquisitions that will complement its core operations.

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.